[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.129.152. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
September 17, 2003

Use of Composite End Points to Measure Clinical Events—Reply

Author Affiliations
 

Letters Section Editor: Stephen J. Lurie, MD, PhD, Senior Editor.

JAMA. 2003;290(11):1456-1457. doi:10.1001/jama.290.11.1456-a

To The Editor: Dr Freemantle and colleagues1 discussed the pros and cons of composite end points in clinical trials and the difficulties in interpreting results when using them. They argued that composite end points can be used to gain statistical power or when there is uncertainty about which single end point to choose. We would like to add a third reason: to be able to define a summary measure for drug efficacy.

First Page Preview View Large
First page PDF preview
First page PDF preview
×